PHS
CDLX icon

Pekin Hardy Strauss’s Cardlytics CDLX Stock Holding History

Pekin Hardy Strauss’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,960
Closed -$243K – 347
2024
Q2 		$243K Buy
+2,960
New +$320K 0.03% 285

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return
BCM
Brightlight Capital Management Westport, Connecticut $101M AUM 23.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Pekin Hardy Strauss's CDLX Position: Q3 2024 in Review

Pekin Hardy Strauss sold out of Cardlytics (CDLX) in Q3 2024, closing a stake of 2,960 shares — an estimated $243K sold.

Pekin Hardy Strauss first reported a position in CDLX in Q2 2024 and held it in 1 quarter. The position peaked at $243K in Q2 2024. 111 funds tracked by Wall St. Rank hold CDLX as of Q3 2024.

  • Pekin Hardy Strauss reported no remaining Cardlytics position as of Q3 2024 after selling out during the quarter.
  • Pekin Hardy Strauss sold 2,960 Cardlytics shares in Q3 2024, an estimated $243K.
  • Pekin Hardy Strauss first reported a position in Cardlytics in Q2 2024 and held it in 1 quarter.
  • Pekin Hardy Strauss's Cardlytics position peaked at $243K in Q2 2024.
  • 111 funds tracked by Wall St. Rank held Cardlytics as of Q3 2024.

Based on Pekin Hardy Strauss's 13F filing for Q3 2024, filed 12 Nov 2024.